000169139 001__ 169139
000169139 005__ 20240229133642.0
000169139 0247_ $$2doi$$a10.1016/j.ygyno.2021.06.001
000169139 0247_ $$2pmid$$apmid:34099314
000169139 0247_ $$2ISSN$$a0090-8258
000169139 0247_ $$2ISSN$$a1095-6859
000169139 0247_ $$2altmetric$$aaltmetric:107298480
000169139 037__ $$aDKFZ-2021-01281
000169139 041__ $$aEnglish
000169139 082__ $$a610
000169139 1001_ $$aDossus, Laure$$b0
000169139 245__ $$aProspective analysis of circulating metabolites and endometrial cancer risk.
000169139 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2021
000169139 3367_ $$2DRIVER$$aarticle
000169139 3367_ $$2DataCite$$aOutput Types/Journal article
000169139 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1627470922_3141
000169139 3367_ $$2BibTeX$$aARTICLE
000169139 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169139 3367_ $$00$$2EndNote$$aJournal Article
000169139 500__ $$a2021 Aug;162(2):475-481
000169139 520__ $$aEndometrial cancer is strongly associated with obesity and dysregulation of metabolic factors such as estrogen and insulin signaling are causal risk factors for this malignancy. To identify additional novel metabolic pathways associated with endometrial cancer we performed metabolomic analyses on pre-diagnostic plasma samples from 853 case-control pairs from the European Prospective Investigation into Cancer and Nutrition (EPIC).A total of 129 metabolites (acylcarnitines, amino acids, biogenic amines, glycerophospholipids, hexoses, and sphingolipids) were measured by liquid chromatography-mass spectrometry. Conditional logistic regression estimated the associations of metabolites with endometrial cancer risk. An analysis focusing on clusters of metabolites using the bootstrap lasso method was also employed.After adjustment for body mass index, sphingomyelin [SM] C18:0 was positively (OR1SD: 1.18, 95% CI: 1.05-1.33), and glycine, serine, and free carnitine (C0) were inversely (OR1SD: 0.89, 95% CI: 0.80-0.99; OR1SD: 0.89, 95% CI: 0.79-1.00 and OR1SD: 0.91, 95% CI: 0.81-1.00, respectively) associated with endometrial cancer risk. Serine, C0 and two sphingomyelins were selected by the lasso method in >90% of the bootstrap samples. The ratio of esterified to free carnitine (OR1SD: 1.14, 95% CI: 1.02-1.28) and that of short chain to free acylcarnitines (OR1SD: 1.12, 95% CI: 1.00-1.25) were positively associated with endometrial cancer risk. Further adjustment for C-peptide or other endometrial cancer risk factors only minimally altered the results.These findings suggest that variation in levels of glycine, serine, SM C18:0 and free carnitine may represent specific pathways linked to endometrial cancer development. If causal, these pathways may offer novel targets for endometrial cancer prevention.
000169139 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169139 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169139 650_7 $$2Other$$aAmino acids
000169139 650_7 $$2Other$$aEndometrial cancer
000169139 650_7 $$2Other$$aLipids
000169139 650_7 $$2Other$$aMetabolomics
000169139 650_7 $$2Other$$aObesity
000169139 7001_ $$aKouloura, Eirini$$b1
000169139 7001_ $$aBiessy, Carine$$b2
000169139 7001_ $$aViallon, Vivian$$b3
000169139 7001_ $$aSiskos, Alexandros P$$b4
000169139 7001_ $$aDimou, Niki$$b5
000169139 7001_ $$aRinaldi, Sabina$$b6
000169139 7001_ $$aMerritt, Melissa A$$b7
000169139 7001_ $$aAllen, Naomi$$b8
000169139 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renee$$b9$$udkfz
000169139 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b10$$udkfz
000169139 7001_ $$aWeiderpass, Elisabete$$b11
000169139 7001_ $$aGram, Inger T$$b12
000169139 7001_ $$aRothwell, Joseph A$$b13
000169139 7001_ $$aLécuyer, Lucie$$b14
000169139 7001_ $$aSeveri, Gianluca$$b15
000169139 7001_ $$aSchulze, Matthias B$$b16
000169139 7001_ $$aNøst, Therese Haugdahl$$b17
000169139 7001_ $$aCrous-Bou, Marta$$b18
000169139 7001_ $$aSánchez, Maria-Jose$$b19
000169139 7001_ $$aAmiano, Pilar$$b20
000169139 7001_ $$aColorado-Yohar, Sandra M$$b21
000169139 7001_ $$aGurrea, Aurelio Barricarte$$b22
000169139 7001_ $$aSchmidt, Julie A$$b23
000169139 7001_ $$aPalli, Domenico$$b24
000169139 7001_ $$aAgnoli, Claudia$$b25
000169139 7001_ $$aTumino, Rosario$$b26
000169139 7001_ $$aSacerdote, Carlotta$$b27
000169139 7001_ $$aMattiello, Amalia$$b28
000169139 7001_ $$aVermeulen, Roel$$b29
000169139 7001_ $$aHeath, Alicia K$$b30
000169139 7001_ $$aChristakoudi, Sofia$$b31
000169139 7001_ $$aTsilidis, Konstantinos K$$b32
000169139 7001_ $$aTravis, Ruth C$$b33
000169139 7001_ $$aGunter, Marc J$$b34
000169139 7001_ $$aKeun, Hector C$$b35
000169139 773__ $$0PERI:(DE-600)1467974-7$$a10.1016/j.ygyno.2021.06.001$$gp. S0090825821004479$$n2$$p475-481$$tGynecologic oncology$$v162$$x0090-8258$$y2021
000169139 909CO $$ooai:inrepo02.dkfz.de:169139$$pVDB
000169139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000169139 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000169139 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169139 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169139 9141_ $$y2021
000169139 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-28$$wger
000169139 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGYNECOL ONCOL : 2019$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000169139 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-28
000169139 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000169139 980__ $$ajournal
000169139 980__ $$aVDB
000169139 980__ $$aI:(DE-He78)C020-20160331
000169139 980__ $$aUNRESTRICTED